STOCK TITAN
  1. Home
  2. Sec-filings
  3. FUSB
  4. [8-K] First US Bancshares, Inc. Reports Material Event

[8-K] First US Bancshares, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Merit Medical Systems (MMSI) – Q2 2025 10-Q highlights

  • Revenue: $382.5 m, up 13.1 % YoY; six-month revenue $737.8 m, up 11.5 %.
  • Mix: Cardiovascular +11 % to $364.0 m; Endoscopy devices +81 % to $18.4 m.
  • Margins: Gross margin 48.3 % (+60 bp); SG&A +19 %, R&D +20 % drove operating margin down 130 bp to 12.3 %.
  • Earnings: Net income $32.6 m (-8.8 %); diluted EPS $0.54 vs $0.61. 1H EPS $1.03 (-5.5 %).
  • Cash flow: 1H operating cash flow $123.9 m (+18 %); capex $34.8 m; acquisitions $122.6 m.
  • Balance sheet: Cash $341.8 m (-9 % YTD); long-term convertible notes $731.8 m; equity $1.49 bn (+7.9 %). Leverage covenants remain compliant.
  • Acquisitions: Closed $126 m Biolife deal in May (hemostatic devices); prior Cook ($210 m) and EGS ($105 m) integrations ongoing. Goodwill now $504.6 m.
  • Tax: Effective rate 24.9 % vs 22.1 %, pressuring earnings.

Overall, strong top-line growth and cash generation were offset by higher operating costs, acquisition spending and a rising tax rate, leading to lower YoY earnings.

Merit Medical Systems (MMSI) – Highlights del 10-Q del secondo trimestre 2025

  • Ricavi: 382,5 milioni di dollari, in crescita del 13,1% su base annua; ricavi semestrali a 737,8 milioni, +11,5%.
  • Composizione: Cardiovascolare +11% a 364,0 milioni; dispositivi per endoscopia +81% a 18,4 milioni.
  • Margini: Margine lordo al 48,3% (+60 punti base); SG&A +19%, R&S +20% hanno ridotto il margine operativo di 130 punti base al 12,3%.
  • Utile: Utile netto 32,6 milioni (-8,8%); EPS diluito 0,54$ contro 0,61$. EPS primo semestre 1,03$ (-5,5%).
  • Flusso di cassa: Flusso operativo primo semestre 123,9 milioni (+18%); investimenti in capitale fisso 34,8 milioni; acquisizioni 122,6 milioni.
  • Bilancio: Liquidità 341,8 milioni (-9% da inizio anno); obbligazioni convertibili a lungo termine 731,8 milioni; patrimonio netto 1,49 miliardi (+7,9%). Covenant di leva finanziaria rispettati.
  • Acquisizioni: Completata a maggio l'acquisizione di Biolife per 126 milioni (dispositivi emostatici); integrazioni in corso di Cook (210 milioni) ed EGS (105 milioni). Avviamento ora a 504,6 milioni.
  • Fiscalità: Aliquota effettiva 24,9% contro 22,1%, con impatto negativo sugli utili.

In sintesi, una forte crescita dei ricavi e generazione di cassa sono state compensate da maggiori costi operativi, spese per acquisizioni e un aumento dell’aliquota fiscale, portando a una diminuzione degli utili su base annua.

Merit Medical Systems (MMSI) – Resumen del 10-Q del segundo trimestre de 2025

  • Ingresos: 382,5 millones de dólares, un aumento del 13,1 % interanual; ingresos semestrales de 737,8 millones, +11,5 %.
  • Composición: Cardiovascular +11 % a 364,0 millones; dispositivos de endoscopia +81 % a 18,4 millones.
  • Márgenes: Margen bruto 48,3 % (+60 puntos básicos); SG&A +19 %, I+D +20 % redujeron el margen operativo en 130 puntos básicos hasta 12,3 %.
  • Ganancias: Ingreso neto 32,6 millones (-8,8 %); EPS diluido 0,54$ frente a 0,61$. EPS primer semestre 1,03$ (-5,5 %).
  • Flujo de caja: Flujo operativo primer semestre 123,9 millones (+18 %); capex 34,8 millones; adquisiciones 122,6 millones.
  • Balance: Efectivo 341,8 millones (-9 % en el año); bonos convertibles a largo plazo 731,8 millones; patrimonio 1,49 mil millones (+7,9 %). Los convenios de apalancamiento permanecen cumplidos.
  • Adquisiciones: Cerrada en mayo la compra de Biolife por 126 millones (dispositivos hemostáticos); integraciones en curso de Cook (210 millones) y EGS (105 millones). Plusvalía ahora 504,6 millones.
  • Impuestos: Tasa efectiva 24,9 % frente a 22,1 %, presionando las ganancias.

En general, un sólido crecimiento en ingresos y generación de caja se vio compensado por mayores costos operativos, gastos en adquisiciones y un aumento en la tasa impositiva, lo que llevó a una disminución de las ganancias interanuales.

Merit Medical Systems (MMSI) – 2025년 2분기 10-Q 주요 내용

  • 매출: 3억 8,250만 달러로 전년 동기 대비 13.1% 증가; 6개월 누적 매출 7억 3,780만 달러로 11.5% 증가.
  • 제품 구성: 심혈관 부문 11% 증가해 3억 6,400만 달러; 내시경 기기 81% 증가해 1,840만 달러.
  • 마진: 총이익률 48.3% (+60bp); 판매관리비 19%, 연구개발비 20% 증가로 영업이익률은 130bp 하락한 12.3%.
  • 수익: 순이익 3,260만 달러(-8.8%); 희석주당순이익 0.54달러, 이전 0.61달러 대비 감소. 상반기 EPS 1.03달러(-5.5%).
  • 현금 흐름: 상반기 영업현금흐름 1억 2,390만 달러(+18%); 자본적지출 3,480만 달러; 인수금액 1억 2,260만 달러.
  • 재무상태: 현금 3억 4,180만 달러(-9% 연초 대비); 장기 전환사채 7억 3,180만 달러; 자본 14억 9,000만 달러(+7.9%). 레버리지 계약 조건 준수 중.
  • 인수합병: 5월에 1억 2,600만 달러 규모의 Biolife 인수 완료(지혈 기기); 이전 Cook(2억 1,000만 달러), EGS(1억 500만 달러) 통합 진행 중. 영업권 현재 5억 460만 달러.
  • 세금: 유효 세율 24.9%로 이전 22.1% 대비 상승, 수익에 부담.

전반적으로 강한 매출 성장과 현금 창출에도 불구하고 운영비 증가, 인수 지출 및 세율 상승으로 인해 전년 대비 수익은 감소했다.

Merit Medical Systems (MMSI) – Points clés du 10-Q du T2 2025

  • Revenus : 382,5 M$, en hausse de 13,1 % en glissement annuel ; revenus semestriels à 737,8 M$, +11,5 %.
  • Répartition : Cardiovasculaire +11 % à 364,0 M$ ; dispositifs d'endoscopie +81 % à 18,4 M$.
  • Marges : Marge brute à 48,3 % (+60 points de base) ; SG&A +19 %, R&D +20 % ont fait baisser la marge opérationnelle de 130 points de base à 12,3 %.
  • Bénéfices : Résultat net 32,6 M$ (-8,8 %) ; BPA dilué 0,54$ contre 0,61$. BPA 1S 1,03$ (-5,5 %).
  • Flux de trésorerie : Flux de trésorerie opérationnel S1 123,9 M$ (+18 %) ; CAPEX 34,8 M$ ; acquisitions 122,6 M$.
  • Bilan : Trésorerie 341,8 M$ (-9 % depuis le début de l'année) ; obligations convertibles à long terme 731,8 M$ ; capitaux propres 1,49 Md$ (+7,9 %). Les clauses de levier restent respectées.
  • Acquisitions : Clôture en mai de l'acquisition de Biolife pour 126 M$ (dispositifs hémostatiques) ; intégrations en cours de Cook (210 M$) et EGS (105 M$). Goodwill désormais à 504,6 M$.
  • Fiscalité : Taux effectif 24,9 % contre 22,1 %, pesant sur les bénéfices.

Dans l’ensemble, une forte croissance du chiffre d’affaires et une bonne génération de trésorerie ont été compensées par des coûts opérationnels plus élevés, des dépenses d’acquisition et une hausse du taux d’imposition, entraînant une baisse des bénéfices en glissement annuel.

Merit Medical Systems (MMSI) – Highlights des 10-Q für Q2 2025

  • Umsatz: 382,5 Mio. USD, ein Anstieg von 13,1 % im Jahresvergleich; Halbjahresumsatz 737,8 Mio. USD, +11,5 %.
  • Mischung: Kardiovaskulär +11 % auf 364,0 Mio. USD; Endoskopiegeräte +81 % auf 18,4 Mio. USD.
  • Margen: Bruttomarge 48,3 % (+60 Basispunkte); SG&A +19 %, F&E +20 % führten zu einem Rückgang der operativen Marge um 130 Basispunkte auf 12,3 %.
  • Erträge: Nettogewinn 32,6 Mio. USD (-8,8 %); verwässertes EPS 0,54 USD gegenüber 0,61 USD. EPS für das erste Halbjahr 1,03 USD (-5,5 %).
  • Cashflow: Operativer Cashflow im ersten Halbjahr 123,9 Mio. USD (+18 %); Investitionen 34,8 Mio. USD; Akquisitionen 122,6 Mio. USD.
  • Bilanz: Zahlungsmittel 341,8 Mio. USD (-9 % seit Jahresbeginn); langfristige Wandelanleihen 731,8 Mio. USD; Eigenkapital 1,49 Mrd. USD (+7,9 %). Verschuldungsvereinbarungen bleiben eingehalten.
  • Akquisitionen: Im Mai Abschluss der Biolife-Übernahme für 126 Mio. USD (hämostatische Geräte); Integration der vorherigen Cook (210 Mio. USD) und EGS (105 Mio. USD) Akquisitionen läuft. Firmenwert jetzt 504,6 Mio. USD.
  • Steuern: Effektiver Steuersatz 24,9 % gegenüber 22,1 %, belastet die Erträge.

Insgesamt wurde das starke Umsatzwachstum und die Cash-Generierung durch höhere Betriebskosten, Akquisitionsausgaben und eine steigende Steuerquote ausgeglichen, was zu einem Rückgang der Gewinne im Jahresvergleich führte.

Positive
  • Revenue growth of 13 % YoY and broad-based segment gains signal strong demand.
  • Gross margin expansion of 60 bp despite inflation indicates pricing/efficiency traction.
  • Operating cash flow up 18 % to $124 m enhances internal funding capacity.
  • Balance-sheet strength: $342 m cash and $697 m unused revolver provide liquidity for further R&D and M&A.
Negative
  • Diluted EPS fell 11 % YoY due to higher SG&A, R&D and tax rate.
  • Net margin compression: operating margin down 130 bp to 12.3 %.
  • Cash balance down 46 % vs prior-year quarter following heavy acquisition spend.
  • Interest expense remains elevated ($6.8 m in Q2) reflecting convertible-debt issuance.

Insights

TL;DR – Solid revenue beat, but cost inflation and taxes eroded EPS; outlook hinges on acquisition synergies.

Double-digit sales growth, particularly in peripheral and endoscopy lines, confirms healthy procedure volumes and early contribution from recent tuck-ins. Gross margin expanded slightly, yet SG&A and R&D rose faster (partly Biolife/Cook integration), trimming operating leverage. Interest and tax headwinds compounded, driving an 11 % EPS decline. Cash generation remains robust and liquidity ample, though cash pile fell following $123 m Biolife payment. Net leverage is manageable (<2× EBITDA est.) under covenant limits. Investors will focus on realizing cost synergies to restore earnings momentum and on potential dilution from 2029 converts if the stock trades above the ~$86.83 strike.

TL;DR – Biolife buy widens wound-closure portfolio and adds IP; integration risk appears contained.

Management paid ~4.2× projected 2025 sales for Biolife, securing patented StatSeal/WoundSeal technology with 12-year amortization life. Goodwill of $38 m signals expectation of cross-selling through Merit’s cardiovascular channel. Prior Cook and EGS assets are bedding in without material P&L disruption. Cumulative intangible amortization will step up (> $80 m in 2026), but cash tax impact is limited. No covenant stress post-deal: $697 m of revolver headroom and senior secured leverage at ~0×. Successful commercialization could lift organic growth above the current low-double-digit rate.

Merit Medical Systems (MMSI) – Highlights del 10-Q del secondo trimestre 2025

  • Ricavi: 382,5 milioni di dollari, in crescita del 13,1% su base annua; ricavi semestrali a 737,8 milioni, +11,5%.
  • Composizione: Cardiovascolare +11% a 364,0 milioni; dispositivi per endoscopia +81% a 18,4 milioni.
  • Margini: Margine lordo al 48,3% (+60 punti base); SG&A +19%, R&S +20% hanno ridotto il margine operativo di 130 punti base al 12,3%.
  • Utile: Utile netto 32,6 milioni (-8,8%); EPS diluito 0,54$ contro 0,61$. EPS primo semestre 1,03$ (-5,5%).
  • Flusso di cassa: Flusso operativo primo semestre 123,9 milioni (+18%); investimenti in capitale fisso 34,8 milioni; acquisizioni 122,6 milioni.
  • Bilancio: Liquidità 341,8 milioni (-9% da inizio anno); obbligazioni convertibili a lungo termine 731,8 milioni; patrimonio netto 1,49 miliardi (+7,9%). Covenant di leva finanziaria rispettati.
  • Acquisizioni: Completata a maggio l'acquisizione di Biolife per 126 milioni (dispositivi emostatici); integrazioni in corso di Cook (210 milioni) ed EGS (105 milioni). Avviamento ora a 504,6 milioni.
  • Fiscalità: Aliquota effettiva 24,9% contro 22,1%, con impatto negativo sugli utili.

In sintesi, una forte crescita dei ricavi e generazione di cassa sono state compensate da maggiori costi operativi, spese per acquisizioni e un aumento dell’aliquota fiscale, portando a una diminuzione degli utili su base annua.

Merit Medical Systems (MMSI) – Resumen del 10-Q del segundo trimestre de 2025

  • Ingresos: 382,5 millones de dólares, un aumento del 13,1 % interanual; ingresos semestrales de 737,8 millones, +11,5 %.
  • Composición: Cardiovascular +11 % a 364,0 millones; dispositivos de endoscopia +81 % a 18,4 millones.
  • Márgenes: Margen bruto 48,3 % (+60 puntos básicos); SG&A +19 %, I+D +20 % redujeron el margen operativo en 130 puntos básicos hasta 12,3 %.
  • Ganancias: Ingreso neto 32,6 millones (-8,8 %); EPS diluido 0,54$ frente a 0,61$. EPS primer semestre 1,03$ (-5,5 %).
  • Flujo de caja: Flujo operativo primer semestre 123,9 millones (+18 %); capex 34,8 millones; adquisiciones 122,6 millones.
  • Balance: Efectivo 341,8 millones (-9 % en el año); bonos convertibles a largo plazo 731,8 millones; patrimonio 1,49 mil millones (+7,9 %). Los convenios de apalancamiento permanecen cumplidos.
  • Adquisiciones: Cerrada en mayo la compra de Biolife por 126 millones (dispositivos hemostáticos); integraciones en curso de Cook (210 millones) y EGS (105 millones). Plusvalía ahora 504,6 millones.
  • Impuestos: Tasa efectiva 24,9 % frente a 22,1 %, presionando las ganancias.

En general, un sólido crecimiento en ingresos y generación de caja se vio compensado por mayores costos operativos, gastos en adquisiciones y un aumento en la tasa impositiva, lo que llevó a una disminución de las ganancias interanuales.

Merit Medical Systems (MMSI) – 2025년 2분기 10-Q 주요 내용

  • 매출: 3억 8,250만 달러로 전년 동기 대비 13.1% 증가; 6개월 누적 매출 7억 3,780만 달러로 11.5% 증가.
  • 제품 구성: 심혈관 부문 11% 증가해 3억 6,400만 달러; 내시경 기기 81% 증가해 1,840만 달러.
  • 마진: 총이익률 48.3% (+60bp); 판매관리비 19%, 연구개발비 20% 증가로 영업이익률은 130bp 하락한 12.3%.
  • 수익: 순이익 3,260만 달러(-8.8%); 희석주당순이익 0.54달러, 이전 0.61달러 대비 감소. 상반기 EPS 1.03달러(-5.5%).
  • 현금 흐름: 상반기 영업현금흐름 1억 2,390만 달러(+18%); 자본적지출 3,480만 달러; 인수금액 1억 2,260만 달러.
  • 재무상태: 현금 3억 4,180만 달러(-9% 연초 대비); 장기 전환사채 7억 3,180만 달러; 자본 14억 9,000만 달러(+7.9%). 레버리지 계약 조건 준수 중.
  • 인수합병: 5월에 1억 2,600만 달러 규모의 Biolife 인수 완료(지혈 기기); 이전 Cook(2억 1,000만 달러), EGS(1억 500만 달러) 통합 진행 중. 영업권 현재 5억 460만 달러.
  • 세금: 유효 세율 24.9%로 이전 22.1% 대비 상승, 수익에 부담.

전반적으로 강한 매출 성장과 현금 창출에도 불구하고 운영비 증가, 인수 지출 및 세율 상승으로 인해 전년 대비 수익은 감소했다.

Merit Medical Systems (MMSI) – Points clés du 10-Q du T2 2025

  • Revenus : 382,5 M$, en hausse de 13,1 % en glissement annuel ; revenus semestriels à 737,8 M$, +11,5 %.
  • Répartition : Cardiovasculaire +11 % à 364,0 M$ ; dispositifs d'endoscopie +81 % à 18,4 M$.
  • Marges : Marge brute à 48,3 % (+60 points de base) ; SG&A +19 %, R&D +20 % ont fait baisser la marge opérationnelle de 130 points de base à 12,3 %.
  • Bénéfices : Résultat net 32,6 M$ (-8,8 %) ; BPA dilué 0,54$ contre 0,61$. BPA 1S 1,03$ (-5,5 %).
  • Flux de trésorerie : Flux de trésorerie opérationnel S1 123,9 M$ (+18 %) ; CAPEX 34,8 M$ ; acquisitions 122,6 M$.
  • Bilan : Trésorerie 341,8 M$ (-9 % depuis le début de l'année) ; obligations convertibles à long terme 731,8 M$ ; capitaux propres 1,49 Md$ (+7,9 %). Les clauses de levier restent respectées.
  • Acquisitions : Clôture en mai de l'acquisition de Biolife pour 126 M$ (dispositifs hémostatiques) ; intégrations en cours de Cook (210 M$) et EGS (105 M$). Goodwill désormais à 504,6 M$.
  • Fiscalité : Taux effectif 24,9 % contre 22,1 %, pesant sur les bénéfices.

Dans l’ensemble, une forte croissance du chiffre d’affaires et une bonne génération de trésorerie ont été compensées par des coûts opérationnels plus élevés, des dépenses d’acquisition et une hausse du taux d’imposition, entraînant une baisse des bénéfices en glissement annuel.

Merit Medical Systems (MMSI) – Highlights des 10-Q für Q2 2025

  • Umsatz: 382,5 Mio. USD, ein Anstieg von 13,1 % im Jahresvergleich; Halbjahresumsatz 737,8 Mio. USD, +11,5 %.
  • Mischung: Kardiovaskulär +11 % auf 364,0 Mio. USD; Endoskopiegeräte +81 % auf 18,4 Mio. USD.
  • Margen: Bruttomarge 48,3 % (+60 Basispunkte); SG&A +19 %, F&E +20 % führten zu einem Rückgang der operativen Marge um 130 Basispunkte auf 12,3 %.
  • Erträge: Nettogewinn 32,6 Mio. USD (-8,8 %); verwässertes EPS 0,54 USD gegenüber 0,61 USD. EPS für das erste Halbjahr 1,03 USD (-5,5 %).
  • Cashflow: Operativer Cashflow im ersten Halbjahr 123,9 Mio. USD (+18 %); Investitionen 34,8 Mio. USD; Akquisitionen 122,6 Mio. USD.
  • Bilanz: Zahlungsmittel 341,8 Mio. USD (-9 % seit Jahresbeginn); langfristige Wandelanleihen 731,8 Mio. USD; Eigenkapital 1,49 Mrd. USD (+7,9 %). Verschuldungsvereinbarungen bleiben eingehalten.
  • Akquisitionen: Im Mai Abschluss der Biolife-Übernahme für 126 Mio. USD (hämostatische Geräte); Integration der vorherigen Cook (210 Mio. USD) und EGS (105 Mio. USD) Akquisitionen läuft. Firmenwert jetzt 504,6 Mio. USD.
  • Steuern: Effektiver Steuersatz 24,9 % gegenüber 22,1 %, belastet die Erträge.

Insgesamt wurde das starke Umsatzwachstum und die Cash-Generierung durch höhere Betriebskosten, Akquisitionsausgaben und eine steigende Steuerquote ausgeglichen, was zu einem Rückgang der Gewinne im Jahresvergleich führte.

false000071780600007178062025-07-302025-07-30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 30, 2025

 

 

First US Bancshares, Inc.

 

(Exact Name of Registrant as Specified in Charter)

 

Delaware

000-14549

63-0843362

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

3291 U.S. Highway 280

Birmingham, Alabama 35243

(Address of Principal Executive Offices, including Zip Code)

Registrant’s telephone number, including area code: (205) 582-1200

N/A

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

FUSB

The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§230.405 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02

Results of Operations and Financial Condition.

 

On July 30, 2025, First US Bancshares, Inc. issued a press release announcing financial results for the quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 to this Form 8-K and is furnished to, but not filed with, the Commission.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)

Exhibits.

 

Exhibit Number

Exhibit

99.1

Press Release dated July 30, 2025

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: July 30, 2025

FIRST US BANCSHARES, INC.

 

 

By:

/s/ Thomas S. Elley

Name:

Thomas S. Elley

Senior Executive Vice President, Treasurer and Assistant Secretary, Chief Financial Officer

 

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

How much did MMSI earn per share in Q2 2025?

Diluted EPS was $0.54, down from $0.61 a year earlier.

What drove Merit Medical Systems’ revenue growth in Q2 2025?

Cardiovascular products added $364 m (+11 %) and endoscopy devices rose 81 % to $18 m, boosted by portfolio realignment and acquisitions.

How large is MMSI’s cash position after the Biolife acquisition?

Cash and cash equivalents were $341.8 million at 30 Jun 2025.

What is the status of Merit’s convertible notes?

The $747.5 m 3.0 % notes mature Feb 1 2029 with an initial conversion price of about $86.83 per share.

Did Merit meet its credit-facility covenants in Q2 2025?

Yes. The company reported compliance with leverage and interest-coverage ratios and has about $697 m borrowing capacity remaining.

What was the effective tax rate for Q2 2025?

The rate increased to 24.9 % from 22.1 % in the prior year.
Stock FUSB logo
First Us Bancsha

NASDAQ:FUSB

FUSB Rankings

#6997 Ranked by Market Cap
#1374 Ranked by Dividends

FUSB Latest News

Jul 30, 2025
First US Bancshares, Inc. Reports Second Quarter 2025 Results
Jul 28, 2025
Scott Cox Joins First US Bank as Senior Commercial Lending Executive
May 21, 2025
FIRST US BANCSHARES, INC. DECLARES CASH DIVIDEND
Apr 30, 2025
First US Bancshares, Inc. Reports First Quarter 2025 Results
Feb 26, 2025
FIRST US BANCSHARES, INC. DECLARES CASH DIVIDEND

FUSB Latest SEC Filings

Jul 30, 2025
[8-K] First US Bancshares, Inc. Reports Material Event
Jul 1, 2025
[Form 4] First US Bancshares, Inc. Insider Trading Activity
Jul 1, 2025
[Form 4] First US Bancshares, Inc. Insider Trading Activity
Jul 1, 2025
[Form 4] First US Bancshares, Inc. Insider Trading Activity
Jul 1, 2025
[Form 4] First US Bancshares, Inc. Insider Trading Activity

FUSB Stock Data

75.75M
4.74M
15.45%
17.67%
0.12%
Banks - Regional
State Commercial Banks
Link
United States
BIRMINGHAM